Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

IGF1R (Insulin-like growth factor 1 receptor)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Labcorp® Plasma Complete™

OncoGuide™ NCC Oncopanel System

Labcorp® Plasma Complete™

OncoGuide™ NCC Oncopanel System

›

IGF1R underexpression	Ewing Sarcoma	IGF1R underexpression	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
IGF1R expression	Thymoma	IGF1R expression	Thymoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
IGF1R amplification	HER2 Positive Breast Cancer	IGF1R amplification	HER2 Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
IGF1R E1218K	Colorectal Cancer	IGF1R E1218K	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
IGF1R I668N	Colorectal Cancer	IGF1R I668N	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
IGF1R expression	Thymic Carcinoma	IGF1R expression	Thymic Carcinoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
IGF1R overexpression	Colorectal Cancer	IGF1R overexpression	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
IGF1R expression	Ewing Sarcoma	IGF1R expression	Ewing Sarcoma	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D
IGF1R expression	Osteosarcoma	IGF1R expression	Osteosarcoma	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D
IGF1R expression	Soft Tissue Sarcoma	IGF1R expression	Soft Tissue Sarcoma	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D
IGF1R overexpression	Colorectal Cancer	IGF1R overexpression	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D
IGF1R overexpression + KRAS mutation	Colorectal Cancer	IGF1R overexpression + KRAS mutation	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D